In the first quarter of 2024, biotech company XOMA Corporation reported robust financial results and announced the U.S. Food and Drug Administration’s (FDA) approval of Day One’s medical breakthrough OJEMDA (tovorafenib). This significant development has precipitated the receipt of a $9 million milestone for XOMA and opens up an additional revenue stream through en
XOMA celebrates $9 Million Milestone from Q1 2024 Financial Results; FDA Approves Day One’s OJEMDA
Published |
Modified
CSIMarket Newsroom | CSIMarket.com
CSIMarket Newsroom | CSIMarket.com
Source for this article: Based on Xoma Corporation’s official statement
For details on how CSIMarket validates financial and corporate news, please review our
Editorial Standards & Fact-Checking Policy
.
Comments